论文部分内容阅读
目的:本研究观察参灵扶正胶囊和清毒胶囊干预无症状艾滋病病毒(HIV)感染者的临床疗效与安全性。方法:将210例无症状HIV感染者按2∶1的比例随机分配到试验组和对照组,前者予中医药辨证治疗,后者予模拟剂,观察发病百分比,CD4+T细胞、CD8+T细胞计数,细胞因子水平,生活质量和不良反应。结果:试验组发病百分比为22.73%,对照组为36.92%,差异有统计学意义(P<0.05);试验组治疗后CD4+T计数及白介素-12(IL-12)水平高于对照组(P<0.05),白介素-6(IL-6)低于对照组(P<0.05);试验组治疗后WHOQOL-HIV-BREF评分项目生理领域、心理领域、独立性领域、总体健康状况和总体生活质量评分增加,高于对照组治疗后的相应评分(P<0.05)。在观察期间,试验组发生不良反应事件6例,对照组2例,差异无统计学意义。结论:中医药干预可延缓HIV感染者进入艾滋病期,降低艾滋病期的发病百分比,提高患者生活质量,安全性良好。
Objective: This study was to observe the clinical efficacy and safety of Shenling Fuzheng Capsule and Qingdu Capsule in the treatment of asymptomatic HIV (HIV) infection. Methods: 210 cases of asymptomatic HIV-infected persons were randomly allocated to experimental group and control group according to the ratio of 2: 1. The former was given traditional Chinese medicine for syndrome differentiation. The latter was given simulant. The percentage of onset, CD4 + T cell, CD8 + T Cell count, cytokine levels, quality of life and adverse reactions. Results: The incidence of experimental group was 22.73% and that of control group was 36.92%, the difference was statistically significant (P <0.05). The CD4 + T count and interleukin -12 (IL-12) (P <0.05), and interleukin-6 (IL-6) was lower than that of the control group (P <0.05). The WHOQOL-HIV-BREF score in the experimental group was significantly lower than that of the control group in physiological, psychological, Quality score increased, higher than the control group after treatment corresponding score (P <0.05). During the observation period, 6 cases of adverse reactions occurred in the experimental group and 2 cases in the control group, with no significant difference. Conclusion: The intervention of traditional Chinese medicine can delay HIV infection in AIDS patients, reduce the incidence of AIDS, improve the quality of life of patients with good safety.